"uuid:ID","rationale","versionIdentifier","instanceType","id"
"5723f8d7-cd60-4079-861d-b6d1d40fabe2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","2","StudyVersion","StudyVersion_1"
